TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24799159

Group type: EXPERIMENTAL
Intervention: Ketamine group (n = 31) received intravenous ketamine 1 mg/kg before incision, followed by 2 μg/kg/minute infusion for 72 hours plus sufentanil patient‐controlled intravenous analgesia after thoracotomy.
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (n = 47) received intravenous 0.9% normal saline and infusion plus sufentanil patient‐controlled intravenous analgesia.
Number of subjects: 78
Study: 22559905

Group type: EXPERIMENTAL
Intervention: Video intervention describing goals-of-care options
Number of subjects: 101

Group type: COMPARATOR
Intervention: Verbal narrative (control) describing goals-of-care options
Number of subjects: 101
Study: 19232412

Group type: EXPERIMENTAL
Intervention: hs-CRP
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: CRP
Number of subjects: 82
Study: 19080323

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy plus Endostar
Number of subjects: 0
Study: 15767771

Group type: EXPERIMENTAL
Intervention: 2% ketoconazole gel
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 2% ketoconazole cream
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combination of 2% ketoconazole and 0.05% desonide
Number of subjects: 45

Group type: COMPARATOR
Intervention: 0.05% desonide gel
Number of subjects: 45

Group type: COMPARATOR
Intervention: Vehicle (unmedicated gel)
Number of subjects: 45
Study: 14666761

Group type: EXPERIMENTAL
Intervention: Yishen Jianpi Yangxue Tongli Therapy (YJYTT)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Clomiphen
Number of subjects: 107
Study: 11022059

Group type: EXPERIMENTAL
Intervention: Surgical intervention (carotid endarterectomy)
Number of subjects: 1648

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 1648
Study: 9029411

Group type: EXPERIMENTAL
Intervention: CSF levels of dopamine, noradrenaline, 3,4‐dihydroxyphenylacetic acid, homovanillic acid, 3‐methoxy‐4‐hydroxyphenylglycol and 5‐hydroxyindole acetic acid, determined by high‐performance liquid chromatography
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: CSF levels of serotonin metabolites
Number of subjects: 26
Study: 1377457

Group type: EXPERIMENTAL
Intervention: 6% HES (molecular weight average: 450,000)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 5% human albumin
Number of subjects: 40
Study: 6316420

Group type: EXPERIMENTAL
Intervention: 5.0 ng/kg/min PGI2 X Na for 72 hrs
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 5.0 ng/kg/min PGI2 X Na infusion abruptly terminated
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 5.0 ng/kg/min PGI2 X Na infusion tapered off over 12 hrs
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 2.5 ng/kg/min PGI2
Number of subjects: 6

Group type: COMPARATOR
Intervention: 0 (buffer)
Number of subjects: 6
Study: 30921762

Group type: EXPERIMENTAL
Intervention: Anodal tDCS of the M1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Anodal tDCS of the DLPFC
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 20
Study: 29926316

Group type: EXPERIMENTAL
Intervention: Multi-component exercise training for 12 weeks
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Executive functioning
Number of subjects: 110
Study: 26476404

Group type: EXPERIMENTAL
Intervention: High intensity interval exercise (HIIE) 10×60s (85‐90%PMax)/75s (50%PMax)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Moderate intensity interval exercise (MIIE) 10×60s (70‐75%PMax)/60s (50%PMax)
Number of subjects: 22
Study: 24486675

Group type: EXPERIMENTAL
Intervention: Enamel microabrasion (GI) using 37% phosphoric acid and pumice
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Microabrasion associated with at-home bleaching (GII) using 10% carbamide peroxide
Number of subjects: 70
Study: 22913289

Group type: EXPERIMENTAL
Intervention: Modified FACIT-F scale
Number of subjects: 2107

Group type: EXPERIMENTAL
Intervention: Original FACIT-F scale
Number of subjects: 2107
Study: 20565455

Group type: EXPERIMENTAL
Intervention: HFA fluticasone/salmeterol (FP/SM) 250/25 microg via pMDI
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: HFA fluticasone/salmeterol (FP/SM) 250/25 microg via spacer (4 puffs)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: HFA fluticasone/salmeterol (FP/SM) 250/25 microg via spacer (8 puffs)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Reference product Seretide (GlaxoSmithKline, UK)
Number of subjects: 2
Study: 17070671

Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive remediation (12-month intervention)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Computer-skills training (control condition)
Number of subjects: 42
Study: 15863468

Group type: EXPERIMENTAL
Intervention: Probiotic (1x10(9)Lactobacillus fermentum VRI‐033 PCC; Probiomics), twice daily for 8 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo, equivalent volume, twice daily for 8 weeks
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Probiotic
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 12546089

Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix allograft (ADMA)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Subepithelial connective tissue grafts (CTG)
Number of subjects: 7
Study: 10802909

Group type: EXPERIMENTAL
Intervention: Nutrient supplements (B vitamins and minerals) administered semi-blinded for the first year, double-blinded in crossover rotations during the second year, and open-label in the ensuing years.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nutrient supplements continued for at least 2 additional years after the 1-year double-blind phase.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Discontinuation of nutrient supplements after the 1-year double-blind phase.
Number of subjects: 20
Study: 8816620

Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist administered intranasally from day 1 of menstrual cycle
Number of subjects: 86

Group type: COMPARATOR
Intervention: Gonadotropin-releasing hormone agonist administered intranasally from day 21 of menstrual cycle
Number of subjects: 86
Study: 1574019

Group type: EXPERIMENTAL
Intervention: PVRV (Purified Vero Rabies Vaccine)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: HDCV (Human Diploid Cell Vaccine)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (PS)
Number of subjects: 90
Study: 3998911

Group type: EXPERIMENTAL
Intervention: Holding room treatment
Number of subjects: 103

Group type: COMPARATOR
Intervention: Hospitalization
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 103
Study: 30801952

Group type: EXPERIMENTAL
Intervention: Lumbar stabilization exercise program (LSEP)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy controls (no intervention)
Number of subjects: 31
Study: 30879451

Group type: EXPERIMENTAL
Intervention: Intraoperative Rotation Control Method (IRCM)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (Group 2)
Number of subjects: 42
Study: 26267817

Group type: EXPERIMENTAL
Intervention: Inactivated triple influenza vaccine (TIV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monovalent anti-A(H1N1)pdm09 vaccine
Number of subjects: 0
Study: 24502372

Group type: EXPERIMENTAL
Intervention: Gain-framed messages
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Loss-framed messages
Number of subjects: 243

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 243
Study: 22472896

Group type: EXPERIMENTAL
Intervention: Mena expression in malignant tumors (salivary duct carcinomas, carcinomas in pleomorphic adenoma, acinic cell carcinomas, squamous cell carcinomas, high-grade mucoepidermoid carcinomas)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Mena expression in benign tumors (pleomorphic adenomas, Warthin's tumors)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Mena expression in normal salivary glands
Number of subjects: 65

Group type: COMPARATOR
Intervention: Mena expression in lymphomas and low-grade mucoepidermoid carcinomas
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Mena expression in endothelial cells of peritumoral vessels
Number of subjects: 65
Study: 21140088

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 50

Group type: COMPARATOR
Intervention: Local anesthesia with sedation
Number of subjects: 50
Study: 17434401

Group type: EXPERIMENTAL
Intervention: 200 mg raltegravir
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: 400 mg raltegravir
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: 600 mg raltegravir
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 16130850

Group type: EXPERIMENTAL
Intervention: Short course of prophylactic antibiotics (administered for < 24 hours)
Number of subjects: 156
Study: 12160501

Group type: EXPERIMENTAL
Intervention: Ultrathin EGD
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional EGD
Number of subjects: 72
Study: 10853565

Group type: EXPERIMENTAL
Intervention: 4% plain prilocaine
Number of subjects: 150

Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 150

Group type: COMPARATOR
Intervention: 2% mepivacaine with 1:20,000 levonordefrin
Number of subjects: 150
Study: 7575822

Group type: EXPERIMENTAL
Intervention: Glycerin enema (1 mL of glycerin mixed with 1 mL of warmed normal saline) within 30 minutes after birth and repeated at 12 hours of age
Number of subjects: 265

Group type: COMPARATOR
Intervention: No glycerin enema throughout their hospital stay
Number of subjects: 265
Study: 2276191

Group type: EXPERIMENTAL
Intervention: Ioxaglate (with sodium)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Iohexol (without sodium)
Number of subjects: 30
Study: 31563272

Group type: EXPERIMENTAL
Intervention: Prolonged intermittent theta burst stimulation (piTBS) monotherapy
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) monotherapy
Number of subjects: 105

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 105
Study: 31172174

Group type: EXPERIMENTAL
Intervention: 0.15% Leu supplementation
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 0.45% Leu supplementation
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 1.05% Leu supplementation
Number of subjects: 240

Group type: COMPARATOR
Intervention: Positive Control (PC) diet
Number of subjects: 240

Group type: COMPARATOR
Intervention: Negative Control (NC) diet
Number of subjects: 240
Study: 28236956

Group type: EXPERIMENTAL
Intervention: Treatment as usual plus a financial reward for each depot of medication received (€30 per month if fully compliant)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Treatment as usual alone
Number of subjects: 169
Study: 26582851

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg p.o. before surgery and 75 mg twice daily in hospital and for 7 days after discharge
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study: 23490761

Group type: EXPERIMENTAL
Intervention: Problem-solving bibliotherapy intervention
Number of subjects: 124
Study: 21692760

Group type: EXPERIMENTAL
Intervention: Sugammadex dosed at 2 mg.kg(‐1) based on ideal body weight + 40%
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sugammadex dosed at 2 mg.kg(‐1) based on ideal body weight
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sugammadex dosed at 2 mg.kg(‐1) based on ideal body weight + 20%
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sugammadex dosed at 2 mg.kg(‐1) based on real body weight
Number of subjects: 100
Study: 19209073

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (3.2 km of interval running, 1:1 work:rest ratio, 3 times a week for 8 weeks at 90% of maximal heart rate)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Number of subjects: 36
Study: 16899730

Group type: EXPERIMENTAL
Intervention: Hippocampal amnesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Short lags
Number of subjects: 0
Study: 15187195

Group type: EXPERIMENTAL
Intervention: Calcitriol
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Maxacalcitol
Number of subjects: 91

Group type: COMPARATOR
Intervention: Calcitriol and Maxacalcitol
Number of subjects: 91
Study: 11693875

Group type: EXPERIMENTAL
Intervention: Artesunate plus sulfadoxine-pyrimethamine
Number of subjects: 105

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine alone
Number of subjects: 105
Study: 9863092

Group type: EXPERIMENTAL
Intervention: Kangke Injection (RSF)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Glucose-insulin-potassium chloride (GIK)
Number of subjects: 76
Study: 7887117

Group type: EXPERIMENTAL
Intervention: Inverse Sequence Induction (ISI) with atracurium 0.6 mg.kg‐1 followed by thiopental 5 mg.kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Rapid Sequence Induction (RSI) with succinylcholine (SUX) precurarized with atracurium 0.06 mg.kg‐1 followed by thiopental 5 mg.kg‐1 and succinylcholine 1.5 mg.kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 2905148

Group type: COMPARATOR
Intervention: Oxazepam 15 mg (active control)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg and 160 mg
Number of subjects: 12
Study: 30015510

Group type: EXPERIMENTAL
Intervention: Partial controlled weightbearing at 40% body weight with crutches for 6 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Nonweightbearing for 6 weeks
Number of subjects: 39
Study: 28595694

Group type: EXPERIMENTAL
Intervention: Deferred stenting
Number of subjects: 510

Group type: COMPARATOR
Intervention: Immediate stent implantation
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Deferred stenting (in subgroup with stent length ≥24 mm)
Number of subjects: 510

Group type: COMPARATOR
Intervention: Immediate stent implantation (in subgroup with stent length ≥24 mm)
Number of subjects: 510
Study: 25758769

Group type: EXPERIMENTAL
Intervention: Saxagliptin (5 or 2.5 mg daily)
Number of subjects: 16592

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16592
Study: 24060088

Group type: EXPERIMENTAL
Intervention: Ropivacaine plus dexamethasone (RD)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Ropivacaine alone (R)
Number of subjects: 200
Study: 19967572

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy including biofeedback tools (CBT-B)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 128
Study: 18384187

Group type: EXPERIMENTAL
Intervention: C index including ties (Ctied,in)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C index excluding ties (Ctied,out)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both C indices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Average value of the two C indices
Number of subjects: 0
Study: 16780741

Group type: EXPERIMENTAL
Intervention: Positive pressure ventilation (PPV) for 2 - 5 days
Number of subjects: 105

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 105
Study: 14693300

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 155

Group type: COMPARATOR
Intervention: Sildenafil
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 155
Study: 10812259

Group type: EXPERIMENTAL
Intervention: morphine, bolus 150 microg/kg + infusion 1 microg/kg per min and 0.5 microg/kg per min
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ketamine, bolus 60 microg/kg + infusion 6 microg/kg per min and 3 microg/kg per min
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 8857004

Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 3145

Group type: COMPARATOR
Intervention: Thrombolytic therapy
Number of subjects: 3145
Study: 1848072

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6317726

Group type: EXPERIMENTAL
Intervention: Directive patient-education group
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 31455792

Group type: COMPARATOR
Intervention: 30-min moderate-intensity exercise before studying word pairs
Number of subjects: 0

Group type: COMPARATOR
Intervention: 30-min moderate-intensity exercise after studying word pairs
Number of subjects: 0

Group type: COMPARATOR
Intervention: 30-min moderate-intensity exercise (before or after encoding)
Number of subjects: 0
Study: 30522501

Group type: EXPERIMENTAL
Intervention: Abatacept 125 mg weekly for 24 weeks
Number of subjects: 424

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 424
Study: 27494516

Group type: EXPERIMENTAL
Intervention: Intra-articular glucocorticoid injections (IAGCIs)
Number of subjects: 99
Study: 24833315

Group type: EXPERIMENTAL
Intervention: Cognitive remediation combined with early intervention service (EIS)
Number of subjects: 117

Group type: COMPARATOR
Intervention: EIS alone
Number of subjects: 117
Study: 23264279

Group type: EXPERIMENTAL
Intervention: Powered Air-Purifying Respirator (PAPR)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Negative Pressure Respirator (NPR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no respirator)
Number of subjects: 20
Study: 20979824

Group type: EXPERIMENTAL
Intervention: Docetaxel 37.5 mg/m² on days 1 and 8, oral capecitabine 950 mg/m² twice daily on days 1-14 (Group A)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m² on days 1, oral capecitabine 950 mg/m² twice daily on days 1-14 (Group B)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Overall clinical response rate for all groups
Number of subjects: 83

Group type: COMPARATOR
Intervention: Comparison of Group A and Group B
Number of subjects: 83
Study: 18570597

Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg plus verapamil sustained release/trandolapril 180/2 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Verapamil sustained release/trandolapril 180/2 mg
Number of subjects: 54
Study: 16533677

Group type: EXPERIMENTAL
Intervention: Combined visit testing (DSS at the same time as other tests)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Separate visit testing (DSS conducted separately from other tests)
Number of subjects: 100
Study: 12593526

Group type: EXPERIMENTAL
Intervention: Beclometasone dipropionate (BDP) suspension for nebulization 2,400 microg day(-1) b.i.d. (n = 103)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) suspension for nebulization 2,000 microg day(-1) b.i.d. (n = 102)
Number of subjects: 205
Study: 10578972

Group type: EXPERIMENTAL
Intervention: NMP179 monoclonal antibody
Number of subjects: 261
Study: 8851320

Group type: EXPERIMENTAL
Intervention: Regimen A: 6 x 0.5 ml per kg body weight
Number of subjects: 12

Group type: COMPARATOR
Intervention: Regimen B: 0.25 ml per kg body weight at gastric pH < 3
Number of subjects: 12
Study: 1654365

Group type: EXPERIMENTAL
Intervention: Rotavirus vaccine strain M37 (10^5-pfu dose) in adults
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Rotavirus vaccine strain M37 (10^4-pfu dose) in infants and children
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Rotavirus vaccine strain M37 (10^5-pfu dose) in infants
Number of subjects: 48

Group type: COMPARATOR
Intervention: Rotavirus vaccine strain M37
Number of subjects: 48
Study: 6347162

Group type: EXPERIMENTAL
Intervention: Group A: vincristine, adriamycin, and dimethyl triazeno imidazole carboxamide (DIC)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Group B: VM‐26, adriamycin, and DIC
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Long bone lesions
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Flat bone lesions
Number of subjects: 27
Study: 29756483

Group type: EXPERIMENTAL
Intervention: GlideScope and modified Magill forceps (Group M)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 70
Study: 28034414

Group type: EXPERIMENTAL
Intervention: SMS reminders regarding adherence to a healthy diet, medication, and smoking cessation
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo group (received general messages)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: SMS reminders
Number of subjects: 160
Study: 25882510

Group type: EXPERIMENTAL
Intervention: Thrombectomy with Solitaire stent retriever and medical therapy (including intravenous alteplase when eligible)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control group (medical therapy alone)
Number of subjects: 206
Study: 23192416

Group type: COMPARATOR
Intervention: Ankle Foot Orthosis (AFO)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Transcutaneous Peroneal Nerve Stimulator (tPNS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: AFO
Number of subjects: 12
Study: 21446902

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg po qD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 17412718

Group type: EXPERIMENTAL
Intervention: Educational programme providing verbal and written advice about exclusive breast-feeding for 6 months
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (no educational programme)
Number of subjects: 89
Study: 16221754

Group type: EXPERIMENTAL
Intervention: Milk thistle (900 mg daily for 14 days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Black cohosh (40 mg daily for 14 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Rifampin (600 mg daily for 7 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Clarithromycin (1000 mg daily for 7 days)
Number of subjects: 16
Study: 12656875

Group type: EXPERIMENTAL
Intervention: Transmandibular implant according to Bosker
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Augmentation of the mandible followed by four endosseous implants
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Insertion of four short endosseous implants
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 60
Study: 12596948

Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin hydrochloride
Number of subjects: 88

Group type: COMPARATOR
Intervention: Topical gentamicin sulfate
Number of subjects: 88